Small Molecules

05 Sep 2019 Infinity Pharmaceuticals Announces the Initiation of Two Clinical Trials Evaluating IPI-549 in Novel Triple Combination Therapies for the Treatment of Solid Tumors
05 Sep 2019 Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor
05 Sep 2019 Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma
05 Sep 2019 Ocuphire Pharma Announces Completion of the First of Two Phase 2b Clinical Trials for Nyxol® Eye Drops
04 Sep 2019 Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019
04 Sep 2019 Rho kinase inhibitor, "Ripasudil Hydrochloride Hydrate" IND application for Phase 2 clinical study in the United States Indication for Corneal Endothelial Diseases [Developmental code: K-321]
04 Sep 2019 Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
04 Sep 2019 Oxurion Completes Enrolment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for the Treatment of Diabetic Macular Edema (DME)
04 Sep 2019 Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation
03 Sep 2019 Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial
03 Sep 2019 Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients
03 Sep 2019 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma
02 Sep 2019 Brilinta reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes in Phase III THEMIS trial
02 Sep 2019 Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint
02 Sep 2019 Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk of Developing the Flu After Contact With an Infected Person by 86 Percent
02 Sep 2019 Genentech Presents Positive Phase III Study Results for One-Dose Xofluza (Baloxavir Marboxil) in Children With the Flu
01 Sep 2019 MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019
01 Sep 2019 Phase 2 data of aprocitentan, Idorsia’s dual endothelin receptor antagonist, presented at ESC 2019
29 Aug 2019 SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid Tumors
29 Aug 2019 VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
29 Aug 2019 OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency
29 Aug 2019 Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
29 Aug 2019 Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations
29 Aug 2019 Acurx Successfully Completes Ph1 Clinical Trial for ACX-362E in CDI
29 Aug 2019 OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113, a Novel Agonist of Chemerin G-Protein Coupled Receptor, in a Mouse Model of Dry Eye Disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up